Evidence map›Paper›PMID 27119101›Full record

ArticleMolecular therapy oncolytics2015

Retargeted oncolytic adenovirus displaying a single variable domain of camelid heavy-chain-only antibody in a fiber protein.

Elisabeth A van Erp, Lyudmila N Kaliberova, Sergey A Kaliberov, David T Curiel

Open access · goldAbstract read
In one paragraph

Article in Molecular therapy oncolytics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.0field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Molecular therapy. Methods & clinical development · 2025
    Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. In vitro functional genetic modification of canine adenovirus type 2 genome by CRISPR/Cas9.Laboratory investigation; a journal of technical methods and pathology · 2021
    Article
  9. Advanced genetic engineering to achieve in vivo targeting of adenovirus utilizing camelid single domain antibody.Journal of controlled release : official journal of the Controlled Release Society · 2021
    Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Elisabeth A van ErpDepartment of Radiation Oncology, School of Medicine, Washington University in St. Louis , St. Louis, Missouri, USA.
Lyudmila N KaliberovaDepartment of Radiation Oncology, School of Medicine, Washington University in St. Louis , St. Louis, Missouri, USA.
Sergey A KaliberovDepartment of Radiation Oncology, School of Medicine, Washington University in St. Louis , St. Louis, Missouri, USA.
David T CurielDepartment of Radiation Oncology, School of Medicine, Washington University in St. Louis , St. Louis, Missouri, USA.
Washington University in St. Louis · US

Funding

UAB / UMN SPORE in Pancreatic CancerP50CA101955 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KLUG, CHRISTOPHER · 2010 to 2014
$11.1M
Targeted-and Image-Based Adenovirus Cancer Therapeutic VectorsR01CA154697 · NCI · WASHINGTON UNIVERSITY · PI CURIEL, DAVID TERRY, MATHIS, J. MICHAEL · 2011 to 2015
$2.4M
NCI NIH HHS P50 CA101955NCI NIH HHS R01 CA154697
6 · The paper itself

Abstract

Conditionally replicative adenoviruses are promising agents for oncolytic virotherapy. Various approaches have been attempted to retarget adenoviruses to tumor-specific antigens to circumvent deficiency of receptor for adenoviral binding and to provide an additional level of tumor specificity. Functional incorporation of highly specific targeting molecules into the viral capsid can potentially retarget adenoviral infection. However, conventional antibodies are not compatible with the cytoplasmic adenovirus capsid synthesis. The goal of this study was to evaluate the utility of single variable domains derived from heavy chain camelid antibodies for retargeting of adenovirus infection. We have combined transcriptional targeting using a tumor-specific promoter with transductional targeting through viral capsid incorporation of antihuman carcinoembryonic antigen single variable domains. Obtained data demonstrated that employment of a single variable domain genetically incorporated into an adenovirus fiber increased specificity of infection and efficacy of replication of single variable domain-targeted oncolytic adenovirus. The double targeting, both transcriptional through the C-X-C chemokine receptor type 4 promoter and transductional using the single variable domain, is a promising means to improve the therapeutic index for these advanced generation conditionally replicative adenoviruses. A successful strategy to transductional retargeting of oncolytic adenovirus infection has not been shown before and therefore we believe this is the first employment of transductional targeting using single variable domains derived from heavy chain camelid antibodies to enhance specificity of conditionally replicative adenoviruses.

Identifiers

PMID27119101
PMCPMC4782946
OpenAlexW2324018586

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.